Endocrine Abstracts

Today there exist no treatment that can improve semen quality in more than 85% of infertile men. Interaction between germ and Sertoli cells is critical for sperm production, and Denosumab, an inhibitor of RANKL, has previously been shown to stimulate sperm production in a fraction of infertile men. Here, we show in a humanized RANKL mouse that Denosumab dose dependently increase germ cell proliferation and testicular weight. RANKL was modified so it can be blocked by Denosumab...

Background and Purpose: Infertility affects 15% of couples globally, and only few treatment options are available. Gonadotropins are classic and potent regulators of ovarian and female reproductive function, but novel endocrine crosstalk appears to exist between gonads and the skeleton that may influence female fertility. One of the new players include the RANKL signalling system, which consists of the receptor activator of nuclear factor κβ ligand (RANKL), the recep...

Currently, no treatment options exist to improve semen quality for the majority of infertile men, but it is well known that the interaction between Sertoli- and germ cells is essential to ensure complete spermatogenesis. A recent study suggested that denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL) signaling, may decrease germ cell apoptosis in human ex vivo testis cultures and stimulate sperm production in some infertile men. Her...